The cellular biology of aging

For most of the history of medicine, aging was treated as background: the process that occurs while individual diseases are studied. That changed in 2013, when López-Otín and colleagues published "The Hallmarks of Aging" in Cell, a framework naming nine distinct, measurable cellular processes that together produce organismal aging.^[1] The paper became one of the most cited in modern biology because it decomposed a poorly defined phenomenon into an enumerated set of processes, each of which can, at least in principle, be studied and targeted.

The 2023 update expanded the list to twelve.^[2] The hallmarks include genomic instability (accumulated DNA damage), telomere attrition (shortening of the protective chromosome caps with each cell division), epigenetic alterations (drift in gene-regulation patterns), mitochondrial dysfunction (declining efficiency and increased leakage in cellular energy production), stem cell exhaustion (depletion of regenerative reserves), cellular senescence, and chronic inflammation. This article concentrates on the last two, because they are the processes that current cell-based and drug interventions most directly target.

Two features of the framework matter for interpreting any claim in longevity medicine. First, the hallmarks are interconnected: DNA damage pushes cells into senescence, senescent cells drive inflammation, and inflammation degrades stem cell function. Interventions rarely affect one process in isolation. Second, each hallmark carries the same evidentiary test: aggravating it should accelerate aging, and easing it should slow aging in animal models. That test, rather than promotional claims, is the standard the rest of this article applies.

In one sentence

Aging, at the cellular level, is the progressive accumulation of damage and dysregulation across roughly twelve interconnected processes; it is not a single clock but a set of declining systems that exacerbate one another.

When a cell accumulates sufficient damage (critically short telomeres, unrepaired DNA breaks, or oncogene activation), it follows one of two paths: it dies by programmed cell death, or it enters senescence, a state in which it permanently stops dividing but remains metabolically active. Senescence originates as a protective mechanism. A damaged cell that cannot divide cannot become a tumor, which is why the machinery exists and why simply disabling it is not a viable intervention.

The problem lies in what senescent cells do while they persist. In 2008, Judith Campisi's group characterized the senescence-associated secretory phenotype, or SASP: senescent cells secrete a continuous stream of inflammatory cytokines, proteases, and growth factors into the surrounding tissue.^[3] A single senescent cell has a limited effect on its tissue. Thousands, accumulating in skin, joints, blood-vessel walls, and organs over decades, become a source of chronic tissue damage: they degrade the surrounding matrix, recruit inflammation, and push neighboring healthy cells toward senescence in turn. Campisi's later review characterized this dual nature as the dark side of tumor suppression.^[8]

Senescent cells accumulate for two reasons. Production rises, because an older body generates senescent cells at a higher rate, and clearance falls. Senescent cells are normally identified and removed by the immune system; natural killer cells recognize the stress ligands senescent cells display and eliminate them, a surveillance system described in detail in this journal's NK cell explainer. With age, that surveillance weakens, so the same period that produces more senescent cells removes fewer of them. The result is a compounding, gradual accumulation that animal studies link directly to shortened healthspan.^[5]

Compare a blood sample from a healthy twenty-five-year-old with one from a healthy seventy-five-year-old, with no infection and no diagnosed disease in either, and the older sample will typically show higher levels of inflammatory markers such as IL-6, TNF-α, and C-reactive protein. In 2000, the Italian immunologist Claudio Franceschi gave this phenomenon its name: inflammaging, the chronic, low-grade, sterile inflammation that develops with age even in the absence of any infection to fight.^[4]

Acute inflammation is a transient response that resolves once its stimulus is cleared. Inflammaging is inflammation that persists at a low level without any pathogen to clear.

The sources of inflammaging reinforce one another. Senescent cells secrete inflammatory signals through the SASP. Aging immune cells respond to those signals less precisely and resolve inflammation more slowly. Damaged mitochondria leak molecular fragments that the immune system misreads as bacterial invaders, because mitochondria are, in evolutionary origin, ancient bacteria. Visceral fat tissue secretes its own inflammatory cytokines. Each source amplifies the others; this is the hallmark interconnection from section one operating as a degenerative feedback loop.

The clinical relevance is well documented: epidemiological studies repeatedly find baseline inflammatory markers among the stronger blood-measurable correlates of frailty, cardiovascular events, and mortality in older adults.^[9] That correlation is what makes inflammaging the most practical target on the list, because inflammation, unlike telomere length, is a process for which medicine has established interventions. The CALERIE randomized trial demonstrated the point directly: two years of moderate calorie restriction lowered circulating inflammatory markers, including C-reactive protein and TNF-α, in healthy non-obese adults.^[10] It is also why immunomodulatory cell therapies target it: the mesenchymal stromal cells described in this journal's MSC explainer act largely by damping exactly this kind of dysregulated inflammatory signaling.

The senescence field's defining experiment came from the Mayo Clinic in 2016. Baker and colleagues engineered mice so that senescent cells could be selectively destroyed on command, then aged the animals with the mechanism active. Median lifespan rose roughly 25 percent; kidneys, hearts, and fat tissue deteriorated more slowly; tumors appeared later.^[5] That result is why senolytics, drugs that push senescent cells into the cell death they escaped, became one of the most funded ideas in aging research. In humans, the field is at an early stage. The first trials showed that a dasatinib-plus-quercetin course reduces senescent-cell burden in human tissue,^[6] which demonstrates that the mechanism transfers. A separate open-label pilot of the same drug combination in idiopathic pulmonary fibrosis found the regimen feasible and reported modest gains in physical function, though without a placebo group those functional results remain preliminary.^[11] However, no senolytic has yet shown improved health outcomes in a large randomized trial, and the accurate summary of the field is promising but unproven.

The cell-therapy line of work targets the inflammaging axis instead. In the University of Miami's randomized phase II trial, older adults with aging frailty received a single intravenous infusion of allogeneic mesenchymal stromal cells or placebo. At six months, the treated groups showed improved six-minute walk distance and a significant drop in circulating TNF-α, the inflammatory marker that inflammaging elevates, with no treatment-related serious adverse events.^[7] This is the strongest randomized human signal behind the systemic protocols described on our anti-aging program page, and its scope should be stated precisely: it was a phase II trial in a specific population, with functional and biomarker endpoints. It is evidence of reduced inflammation and improved function. It is not evidence of extended lifespan, and no therapy currently has such evidence in humans. Which cell population is infused is itself an open research variable; the Muse cell subpopulation profiled in this journal's Muse cell article is one example of the more defined preparations now under study.

The interventions that failed are equally instructive. Young-blood plasma transfusions, marketed briefly in the United States, produced no convincing trial benefit and drew an FDA warning. Telomerase activation remains constrained by the tumor-suppression trade-off described in section two. The pattern across the field is consistent: interventions aimed at a single hallmark in isolation have repeatedly disappointed, while the durable results, exercise above all, come from interventions that affect several hallmarks at once.

The science provides a filter for evaluating marketing claims. No product sold today, whether drug, supplement, or cell infusion, has been shown to extend human lifespan, and a provider claiming otherwise is displaying the red flags catalogued in our article on safety and vetting. What the evidence does support is narrower but clinically meaningful: inflammaging is real and measurable in standard blood work; senescent-cell burden is a genuine driver of tissue aging; and a randomized human trial has shown that a single MSC infusion can lower inflammatory markers and improve physical function in frail older adults.^[7]

That framing is how TrueCell physicians present the longevity protocols: systemic infusions aimed at the inflammatory axis of aging, anchored to biomarkers measured before and after treatment (CRP, TNF-α, IL-6) rather than to claims about added years of life. A protocol that changes measured inflammatory markers and measured function has produced a real effect, and one the trial literature indicates is achievable. A protocol sold as extending lifespan has departed from the evidence.

The least glamorous conclusion remains true here as elsewhere in this journal. Exercise is the best-documented multi-hallmark intervention known; it improves mitochondrial function, stem cell activity, and inflammatory tone simultaneously. Exercise, sleep, and metabolic health are the baseline from which any evidence-based longevity plan starts. Cellular medicine, where it is supported, belongs on top of that foundation, not in place of it.

Can stem cells reverse aging?

No. No cell therapy has been shown to reverse aging or extend human lifespan, and any provider claiming otherwise has departed from the evidence. What randomized trial data do show is narrower: an MSC infusion can lower specific inflammatory markers and improve measured physical function in frail older adults.

What does an MSC infusion actually do for longevity?

The best-supported mechanism is immunomodulation: infused MSCs damp the chronic low-grade inflammation that rises with age, which trials have tracked as reductions in markers such as TNF-α. In the Miami phase II frailty trial, that biological change was accompanied by improved six-minute walk distance at six months. Whether repeated infusions produce durable benefit in healthier adults has not been established.

What evidence exists in humans so far?

Human evidence is early-stage. Senolytic drugs have been shown to reduce senescent-cell burden in small pilot trials, and one randomized phase II trial found an allogeneic MSC infusion improved function and lowered inflammation in aging frailty. No intervention of either kind has demonstrated improved long-term health outcomes or lifespan in a large randomized trial.